HN2005000016A - Procedimiento de preparacion - Google Patents

Procedimiento de preparacion

Info

Publication number
HN2005000016A
HN2005000016A HN2005000016A HN2005000016A HN2005000016A HN 2005000016 A HN2005000016 A HN 2005000016A HN 2005000016 A HN2005000016 A HN 2005000016A HN 2005000016 A HN2005000016 A HN 2005000016A HN 2005000016 A HN2005000016 A HN 2005000016A
Authority
HN
Honduras
Prior art keywords
preparation procedure
oxo
procedure
preparation
thiophenocarboxamide
Prior art date
Application number
HN2005000016A
Other languages
English (en)
Inventor
Berwe Mathias
Thomas Christian
Rehse Joachim
Grotjohann Dirk
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34716548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HN2005000016(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of HN2005000016A publication Critical patent/HN2005000016A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION DE 5-CLORO-N-({(5S)-2-OXO-3-[4-(3-OXO-4-MORFOLINIL)FENIL-1,3-OXAZOLIDIN-5-IL}-2-TIOFENOCARBOXAMIDA A PARTIR DE 2-[(2S)-2-OXIRANILMETIL-1H-ISOINDOL-1,3(2H)-DIONA,4-(4-AMINOFENIL)-3-MORFOLINONA Y CLORURO DE 5-CLOROTIOFENO-2-CARBONILO.
HN2005000016A 2004-01-15 2005-01-13 Procedimiento de preparacion HN2005000016A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004002044A DE102004002044A1 (de) 2004-01-15 2004-01-15 Herstellverfahren

Publications (1)

Publication Number Publication Date
HN2005000016A true HN2005000016A (es) 2009-06-01

Family

ID=34716548

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2005000016A HN2005000016A (es) 2004-01-15 2005-01-13 Procedimiento de preparacion

Country Status (33)

Country Link
US (1) US7351823B2 (es)
EP (1) EP1720866B1 (es)
JP (2) JP5311742B2 (es)
KR (1) KR20130004257A (es)
CN (1) CN1906191B (es)
AR (1) AR047389A1 (es)
AT (1) ATE518856T1 (es)
AU (1) AU2004313694B2 (es)
BR (1) BRPI0418405B8 (es)
CA (1) CA2553237C (es)
CY (1) CY1112565T1 (es)
DE (1) DE102004002044A1 (es)
DK (1) DK1720866T3 (es)
EC (1) ECSP066703A (es)
ES (1) ES2369140T3 (es)
GT (1) GT200400277A (es)
HK (1) HK1103722A1 (es)
HN (1) HN2005000016A (es)
HR (1) HRP20110796T1 (es)
IL (1) IL176767A (es)
MA (1) MA28290A1 (es)
MY (1) MY138944A (es)
NO (1) NO335553B1 (es)
NZ (1) NZ548506A (es)
PE (1) PE20050763A1 (es)
PL (1) PL1720866T3 (es)
PT (1) PT1720866E (es)
RU (1) RU2383540C2 (es)
SI (1) SI1720866T1 (es)
TW (1) TWI340137B (es)
UY (1) UY28718A1 (es)
WO (1) WO2005068456A1 (es)
ZA (1) ZA200605747B (es)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE10355461A1 (de) 2003-11-27 2005-06-23 Bayer Healthcare Ag Verfahren zur Herstellung einer festen, oral applizierbaren pharmazeutischen Zusammensetzung
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung
EP1685841A1 (en) 2005-01-31 2006-08-02 Bayer Health Care Aktiengesellschaft Prevention and treatment of thromboembolic disorders
DE102005045518A1 (de) 2005-09-23 2007-03-29 Bayer Healthcare Ag 2-Aminoethoxyessigsäure-Derivate und ihre Verwendung
CA2624310C (en) * 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
DE102005047561A1 (de) 2005-10-04 2007-04-05 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit schneller Wirkstofffreisetzung
DE102005047564A1 (de) * 2005-10-04 2007-05-31 Bayer Healthcare Ag Amorphe Form von 5-Chlor-N-({(5S)2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl)-methyl)-2-thiophencarboxamid
DE102005047558A1 (de) * 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102006007146A1 (de) 2006-02-16 2007-08-23 Bayer Healthcare Ag Aminoacyl-Prodrugs
DE102006039589A1 (de) * 2006-08-24 2008-03-06 Bayer Healthcare Ag Aminoacyl-Prodrugs II
DE102006051625A1 (de) * 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
DE102007028407A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
DE102007028319A1 (de) * 2007-06-20 2008-12-24 Bayer Healthcare Ag Substituierte Oxazolidinone und ihre Verwendung
WO2009018807A1 (de) * 2007-08-06 2009-02-12 Schebo Biotech Ag Oxazolidinone als faktor xa- inhibitoren, verfahren zu ihrer herstellung und ihre verwendung in der therapie
US8706950B2 (en) 2008-03-01 2014-04-22 Kabushiki Kaisha Toshiba Memory system
DE102008028071A1 (de) 2008-06-12 2009-12-17 Bayer Schering Pharma Aktiengesellschaft Neue Cokristall-Verbindung von Rivaroxaban und Malonsäure
US20100168111A1 (en) * 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
US8309547B2 (en) * 2009-04-28 2012-11-13 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
US8435989B2 (en) * 2009-04-28 2013-05-07 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
US7816355B1 (en) 2009-04-28 2010-10-19 Apotex Pharmachem Inc Processes for the preparation of rivaroxaban and intermediates thereof
EP2459555B1 (en) 2009-07-31 2021-11-03 KRKA, D.D., Novo Mesto Processes for crystallization of rivaroxaban
US20120283434A1 (en) * 2010-01-04 2012-11-08 Enantia, S.L. Process for the preparation of rivaroxaban and intermediates thereof
DE102010028362A1 (de) 2010-04-29 2011-11-03 Bayer Schering Pharma Aktiengesellschaft Herstellverfahren
EP2388260A1 (de) 2010-05-21 2011-11-23 Archimica GmbH Herstellungsverfahren für einen Inhibitor eines Blutgerinnungsfaktors
CN102311400A (zh) * 2010-06-29 2012-01-11 翔真生物科技股份有限公司 制备5-左旋-氨甲基-3-芳基-2-恶唑烷酮类的方法
EP2404920A1 (en) 2010-07-06 2012-01-11 Sandoz AG Crystalline form of Rivaroxaban dihydrate
US20130253187A1 (en) * 2010-09-14 2013-09-26 Medichem, S.A. Process for Determining the Suitability for Distribution of a Batch of Thiophene-2-Carboxamide Derivative
CZ2010714A3 (cs) * 2010-09-30 2012-04-11 Farmak, A. S. Zpusob výroby 2-({(5S)-2-oxo-3-[4-(3-oxo-4-morfolinyl)fenyl]-1,3oxazolidin-5-yl}methyl)-1H-isoindol-1,3(2H)-dionu ve vysoké optické cistote
WO2012051692A1 (en) 2010-10-18 2012-04-26 Apotex Pharmachem Inc. Processes for the preparation of rivaroxaban and intermediates thereof
UA114601C2 (uk) * 2011-05-06 2017-07-10 Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі
WO2012156983A1 (en) * 2011-05-16 2012-11-22 Symed Labs Limited Processes for the preparation of 5-chloro-n-({(5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl) phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide
ES2395304B1 (es) 2011-05-20 2014-01-16 Interquim, S.A. Procedimiento de obtención de una tiofen-2-carboxamida.
CN102250076A (zh) * 2011-05-27 2011-11-23 横店集团家园化工有限公司 一种利伐沙班中间体及利伐沙班的制备方法
CN102827154B (zh) 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
EP2753619A2 (en) 2011-09-08 2014-07-16 Cadila Healthcare Limited Processes and intermediates for preparing rivaroxaban
WO2013053739A1 (en) 2011-10-10 2013-04-18 Laboratorios Lesvi, S. L. Process for preparing factor xa inhibitors
WO2013121436A2 (en) * 2012-02-06 2013-08-22 Megafine Pharma (P) Ltd A process for preparation of rivaroxaban and intermediates thereof
CZ2012114A3 (cs) * 2012-02-17 2013-02-20 Zentiva, K.S. Zpusob prípravy rivaroxabanu zalozený na úspore 1,1´ -karbonyldiimidazolu
CN103288814B (zh) 2012-02-24 2016-07-06 国药集团国瑞药业有限公司 一种利伐沙班中间体的制备方法
CN102659756A (zh) * 2012-04-01 2012-09-12 南京哈柏医药科技有限公司 5-氯-2-酰氯噻吩的合成方法
EP2834235A1 (en) 2012-04-06 2015-02-11 Indiana University Research and Technology Corporation Processes for preparing rivaroxaban
BR112014027248B1 (pt) 2012-05-02 2021-01-26 Symed Labs Limited processo em um único recipiente para preparar rivaroxaban
CN102757424B (zh) * 2012-07-09 2014-10-15 云南大学 2-苄基取代苯并呋喃—咪唑盐类化合物及其制备方法
CN102746288B (zh) * 2012-07-24 2015-04-08 常州制药厂有限公司 一种抗凝血药及其关键中间体的制备方法
WO2014020458A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban
CN102786516B (zh) * 2012-08-21 2014-10-01 湖南师范大学 一种利伐沙班的合成方法
CN103833724A (zh) * 2012-11-20 2014-06-04 上海医药工业研究院 一种5-氯噻吩-2-甲酰氯的制备方法
CN103864771A (zh) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 一种利伐沙班的制备方法
CN103864772A (zh) * 2012-12-13 2014-06-18 北京京卫信康医药科技发展有限公司 一种利伐沙班及其中间体的制备方法
ES2647607T3 (es) * 2012-12-21 2017-12-22 Farma Grs, D.O.O. Procedimiento para la preparación de rivaroxabán
CA2883323A1 (en) 2012-12-26 2014-07-03 Wanbury Ltd. Aldehyde derivative of substituted oxazolidinones
HUE032850T2 (en) 2012-12-26 2017-11-28 Wanbury Ltd Rivaroxaban intermediate and its preparation
US9663505B2 (en) 2013-03-25 2017-05-30 Glenmark Pharmaceuticals Limited Process for the preparation of rivaroxaban
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
CN103275061A (zh) * 2013-06-04 2013-09-04 上海同昌生物医药科技有限公司 一种生产5-氯噻吩-2-羧酸的方法
CN103351385A (zh) * 2013-06-28 2013-10-16 浙江燎原药业有限公司 一种利伐沙班中间体的制备方法
CN103709116B (zh) * 2013-12-10 2015-09-23 四川大学 一种4-(4-烷氧羰氨基)苯基-3-吗啉酮的制备方法
CN103724336B (zh) * 2013-12-24 2015-10-21 悦康药业集团有限公司 一种新型抗凝血药物的合成方法
WO2015104605A1 (en) 2014-01-08 2015-07-16 Wockhardt Limited A process for preparing rivaroxaban or a pharmaceutically acceptable salt thereof
WO2015111076A2 (en) 2014-01-23 2015-07-30 Symed Labs Limited Improved processes for the preparation of highly pure rivaroxaban crystal modification i
CN105085370B (zh) * 2014-04-22 2017-04-12 北大方正集团有限公司 (s)‑1‑卤代‑2‑[2‑(1,3‑二氧异吲哚)基]乙基氯甲酸酯及其制备方法
WO2015188787A1 (en) * 2014-06-14 2015-12-17 Sunshine Lake Pharma Co., Ltd. Method for preparing oxazolidinone compound and intermediates thereof
CN104086539A (zh) * 2014-07-17 2014-10-08 天津炜捷制药有限公司 一种利伐沙班的制备方法
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN104211694A (zh) * 2014-08-14 2014-12-17 广东东阳光药业有限公司 一种改进的制备Xa因子抑制剂的方法
EP3186246A1 (en) * 2014-08-25 2017-07-05 Cipla Limited Process for the preparation of rivaroxaban
EP3209661B1 (en) 2014-10-22 2021-02-17 Zaklady Farmaceutyczne Polpharma SA Process for preparing a polymorph of rivaroxaban
CN104807934B (zh) * 2015-04-30 2017-01-18 成都百裕制药股份有限公司 异吲哚二酮类化合物的正相高效液相色谱检测方法
CN105130976A (zh) * 2015-08-26 2015-12-09 浙江车头制药股份有限公司 一种利伐沙班中间体的合成方法
CN105440028B (zh) * 2015-12-07 2018-03-13 石家庄康贺威药业有限公司 一种利伐沙班化合物及其制备方法
CN106008490B (zh) * 2016-01-11 2019-01-04 南京生命能科技开发有限公司 一种利伐沙班的新晶体及其制备方法
CN106977507A (zh) * 2017-04-21 2017-07-25 上海华源医药科技发展有限公司 一种利伐沙班的制备方法
CN109553611A (zh) * 2017-09-23 2019-04-02 齐鲁制药有限公司 利伐沙班中间体的制备方法和用途
IL275443B (en) * 2018-02-26 2022-07-01 Sumitomo Chemical Co Production method for an oxazolidinan compound
JP7339754B2 (ja) * 2019-03-27 2023-09-06 ダイト株式会社 中間体の製造方法
CN112521380A (zh) * 2020-12-14 2021-03-19 哈尔滨珍宝制药有限公司 一种利伐沙班中间体a的合成方法及其在制备利伐沙班中的应用
MX2023014072A (es) * 2021-05-28 2023-12-08 Merck Sharp & Dohme Llc Sintesis del inhibidor de la btk e intermediarios del mismo.
EP4201933A1 (en) 2021-12-23 2023-06-28 Zaklady Farmaceutyczne Polpharma S.A. Crystallisation process for rivaroxaban

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) * 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) * 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) * 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid

Also Published As

Publication number Publication date
JP2012097106A (ja) 2012-05-24
AR047389A1 (es) 2006-01-18
CN1906191B (zh) 2010-05-26
DE102004002044A1 (de) 2005-08-04
CA2553237C (en) 2012-04-17
NZ548506A (en) 2009-06-26
JP2007517816A (ja) 2007-07-05
WO2005068456A1 (de) 2005-07-28
CN1906191A (zh) 2007-01-31
ZA200605747B (en) 2007-10-31
ECSP066703A (es) 2006-10-31
AU2004313694A1 (en) 2005-07-28
DK1720866T3 (da) 2011-11-21
IL176767A (en) 2011-04-28
UY28718A1 (es) 2005-08-31
HK1103722A1 (en) 2007-12-28
AU2004313694B2 (en) 2011-06-02
EP1720866B1 (de) 2011-08-03
SI1720866T1 (sl) 2012-01-31
RU2383540C2 (ru) 2010-03-10
ES2369140T3 (es) 2011-11-25
TWI340137B (en) 2011-04-11
PE20050763A1 (es) 2005-12-02
MY138944A (en) 2009-08-28
CY1112565T1 (el) 2016-02-10
KR20130004257A (ko) 2013-01-09
EP1720866A1 (de) 2006-11-15
NO20063677L (no) 2006-10-11
BRPI0418405B8 (pt) 2021-05-25
US7351823B2 (en) 2008-04-01
CA2553237A1 (en) 2005-07-28
TW200604195A (en) 2006-02-01
RU2006129341A (ru) 2008-02-20
ATE518856T1 (de) 2011-08-15
MA28290A1 (fr) 2006-11-01
JP5311742B2 (ja) 2013-10-09
GT200400277A (es) 2005-08-18
BRPI0418405A (pt) 2007-05-15
PL1720866T3 (pl) 2012-01-31
IL176767A0 (en) 2006-10-31
BRPI0418405B1 (pt) 2018-03-13
US20050182055A1 (en) 2005-08-18
PT1720866E (pt) 2011-10-12
NO335553B1 (no) 2014-12-29
HRP20110796T1 (hr) 2011-12-31

Similar Documents

Publication Publication Date Title
HN2005000016A (es) Procedimiento de preparacion
MEP50608A (en) 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridine-2-yl-amino]-propionic acid ethyl ester methane sulphonate and use thereof as a medicament
UY29493A1 (es) Sales fisiológicamente compatibles de éster etílico del ácido 3-((2-((4-(hexiloxicarbonilamino-imino-metil)-fenilamino)-metil)-1-metil-1h-bencimidazol-5-carbonil)-piridin-2-il-amino)-propiónico
CY2013036I1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
CY1113158T1 (el) Χορηγουμενη απο του στοματος φαρμακοτεχνικη μορφη για τον 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλ}-1-μεθυλ-1η-βενζιμιδαζολο-5-καρβονυλο)-πυριδιν-2-υλ-αμινο]-προπιονικο αιθυλεστερα ή τα αλατα αυτου
RS54445B1 (en) 3,5-DIAMINO-6-CHLORO-N- (N- (4- (4- (2- (HEXYL (2,3,4,5,6-PENTAHYDROXYHEXYL) AMINO) ETHOXY) PHENYL) BUTYL) CARBAMIMIDOIL) PYRAZINE -2-CARBOXAMIDE
CY1112467T1 (el) Παραγωγα 1-θειο-d-γλυκιτολης
CR10702A (es) Hidratos de 2-cloro-5-[3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil]-4-fluor-n-{{metil(1-metiletil)amino]sulfonil]benzamida
PA8649401A1 (es) Analogos de anilino-pirimidina
IN2014DN08578A (es)
RS52681B (en) HYDROBENZOATE SALTS OF METHANICOTINE COMPOUND
DK1578733T3 (da) Fremgangsmåde til fremstilling af rosuvastatin
EA200970372A1 (ru) Ингибитор развития болезни альцгеймера, содержащий гетероциклическое соединение
DE602005003312D1 (de) Kompositrakel
DK1608309T3 (da) 10,10-Dialkylprostanoidsyrederivater som midler til reduktion af det intraokulare tryk
DE602007014036D1 (de) 12-aryl-prostaglandin-analoga
MA30042B1 (fr) Composes calcilytiques
BRPI0713314A2 (pt) Processo para a preparação de 3-(2-hidróxi-5-fenil substituído)-n-alquil-3-fenilpropilaminas
HN2011000745A (es) Sales de n-[6-cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4´-(triflouro-metoxi)-[1,1´-bifenil]-3-carboxamida
RS52351B (en) 5- (2,4-Dihydroxy-5-isopropyl-phenyl) -4- (4-morpholine-4-ylmethyl-phenyl) -isoxazole-3-carboxylic acid ethylamide mesylate, their hydrates and polymorphs, and formulations thereof
TW200740769A (en) Novel process
ITTO20060879A1 (it) Unita' per la costruzione di solette a cialda.
EA200700191A1 (ru) Композиции, содержащие никорандил, способ получения и применение
ITMI20060488A1 (it) Procedimento per la preparazione di 3,4-bis trifluoronetil-n-metilbenzilammina
ECSP034708A (es) Nueva sal de benzoilguanidina